Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model

被引：7

作者：

Matsumoto, Shuhei ^{[1
]}

Kanazawa, Sachi ^{[2
]}

Sato, Takafumi ^{[2
]}

Yamano, Yoshinori ^{[2
]}

机构：

[1] Shionogi & Co Ltd, Business Dev, Osaka, Japan

[2] Shionogi & Co Ltd, Drug Discovery & Dis Res Lab, Osaka, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 11期

关键词：

cefiderocol; carbapenem resistant; Enterobacterales; Acinetobacter baumannii; chemostat model; nonfermenters; COLISTIN;

D O I：

10.1128/AAC.01128-20

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Activities of cefiderocol under simulated human plasma concentrations at the recommended dosing regimen of 2 g every 8 h with a 3-h infusion were evaluated using an in vitro chemostat model. Against a total of 6 meropenem-resistant Gram-negative strains with cefiderocol MICs of 0.5 to 4 mu g/ml, including metallo-beta-lactamase producers and carbapenem-resistant Acinetobacter baumannii, cefiderocol treatment showed a bactericidal effect within 8 h and sustained efficacy with no marked bacterial regrowth over 24 h.

引用

收藏

页数：5

相关论文

共 19 条

[1] Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients [J].

Alhadab, Ali A. ;

Ahmed, Mariam A. ;

Brundage, Richard C. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (04)

[2] Metallo-β-lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods [J].

Asempa, Tomefa E. ;

Abdelraouf, Kamilia ;

Nicolau, David P. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (04) :997-1005

[3] Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections [J].

Cai, Bingxuan ;

Cai, Yiying ;

Liew, Yi Xin ;

Chua, Nathalie Grace ;

Teo, Jocelyn Qi-Min ;

Lim, Tze-Peng ;

Kurup, Asok ;

Ee, Pui Lai Rachel ;

Thuan Tong Tan ;

Lee, Winnie ;

Kwa, Andrea Lay-Hoon .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (07) :4013-4022

[4]

Clinical and Laboratory Standards Institute, 2019, M100ED29 CLSI

[5]

Committee for Medicinal Products for Human Use (CHMP), 2020, Assessment report

[6] Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA [J].

Endimiani, Andrea ;

Hujer, Andrea M. ;

Perez, Federico ;

Bethel, Christopher R. ;

Hujer, Kristine M. ;

Kroeger, Jennifer ;

Oethinger, Margret ;

Paterson, David L. ;

Adams, Mark D. ;

Jacobs, Michael R. ;

Diekema, Daniel J. ;

Hall, Gerri S. ;

Jenkins, Stephen G. ;

Rice, Louis B. ;

Tenover, Fred C. ;

Bonomo, Robert A. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (03) :427-437

[7]

FDA, 2019, CEF INJ

[8] Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth [J].

Hackel, Meredith A. ;

Tsuji, Masakatsu ;

Yamano, Yoshinori ;

Echols, Roger ;

Karlowsky, James A. ;

Sahm, Daniel F. .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2019, 94 (04) :321-325

[9] In Vitro Pharmacokinetic and Pharmacodynamic Evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae [J].

Homma, Tomoyuki ;

Hori, Toshihiko ;

Ohshiro, Merime ;

Maki, Hideki ;

Yamano, Yoshinori ;

Shimada, Jingoro ;

Kuwahara, Shogo .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (10) :4300-4305

[10] Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen [J].

Kato, Hideo ;

Hagihara, Mao ;

Hirai, Jun ;

Sakanashi, Daisuke ;

Suematsu, Hiroyuki ;

Nishiyama, Naoya ;

Koizumi, Yusuke ;

Yamagishi, Yuka ;

Matsuura, Katsuhiko ;

Mikamo, Hiroshige .

DRUGS IN R&D, 2017, 17 (01) :177-187